GlassScriptPhysician profile
Haley Lippmeier
NPI 1508467192
$605.55
in general payments reported to CMS, 2019-2025
10 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $232 · 2024: $259 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $356.26 | 2024-2025 | Airsupra, Breztri |
| Abbvie INC. | $53.87 | 2023 | |
| Novo Nordisk INC | $44.67 | 2023 | Rybelsus, Ozempic, Saxenda |
| Exact Sciences Corporation | $42.71 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $26.19 | 2023 | Auvelity |
| Sanofi Pasteur INC. | $20.56 | 2023 | |
| Pulmonx Corporation | $16.87 | 2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.72 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.61 | 2023 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $13.09 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Lippmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.